Oleoylethanolamide vs Berberine

Oleoylethanolamide wins for cumulative appetite suppression, non-stimulant satiety, mild hepatic and metabolic support, and lack of GI side effects at standard research doses. It's reliable for stretching inter-meal intervals and gently tightening dietary compliance in polished cuts or when mitigating rebound hunger after GLP-1 cycles.

Berberine wins for metabolic flexibility: robust improvements in fasting glucose, HbA1c, triglycerides, and cholesterol, with direct support for on-cycle lipid management and carb partitioning. Its AMPK activation and metformin-parity make it the superior research pick for managing impaired glucose tolerance or oral-induced dyslipidemia. Data also supports synergy with GH/slin protocols. GI distress is its main limitation, though the dihydroberberine forms mitigate this in most regimens.

Pick Oleoylethanolamide if:

• Continuous appetite suppression and satiety are key goals in a recomp or late-stage cut protocol.
• The research aims to support liver health markers (ALT, AST, GGT) without adding stimulants.
• Taming "food noise" post GLP-1 cycles is needed without risking hypoglycemia.
• Non-hormonal, non-stimulant research is preferred to avoid CNS or endocrine interference.
• The study design involves pairing with GLP-1s, orals, or other non-androgenic agents for compliance.

Pick Berberine if:

• The protocol requires significant improvement of glucose, lipid, or insulin sensitivity markers (HbA1c, LDL, triglycerides).
• On-cycle lipid rescue is needed in oral-AAS or GH/slin stacking designs.
• The research focus is on carb partitioning and metabolic health, not direct fat-loss or appetite suppression.
• Prior GI tolerance exists or dihydroberberine is available to minimize distress.
• There's a need for a metformin-like agent without prescription constraint, especially for long-term protocols.